Bypassing Withdrawal: How "Direct-to-Inject" is Changing Opioid Recovery

For years, individuals struggling with Opioid Use Disorder (OUD) faced a major roadblock on day one of recovery: the fear of withdrawal. When a person decides to start treatment using medication-assisted treatment (MAT), buprenorphine is one of the most reliable and lifesaving options available. It acts as a partial shield on brain receptors, satisfying cravings and cutting the risk of fatal overdose.

However, the street drug supply has radically changed. Heroin has largely been replaced by illicitly manufactured fentanyl, an incredibly high-potency synthetic opioid. Fentanyl acts differently inside the human body. Because it dissolves easily and stores itself inside body fat tissues, it lingers in a person’s system for a long time, even after they stop feeling high. This unique chemistry makes starting traditional sublingual (under-the-tongue) buprenorphine incredibly difficult.

If a patient takes a standard oral dose of buprenorphine while fentanyl is still attached to their brain receptors, the buprenorphine accidentally tears the remaining fentanyl away too fast, throwing the patient into a severe, sudden state of illness known as precipitated withdrawal. This negative experience can deter individuals from pursuing treatment altogether. 

To overcome this barrier, a breakthrough medical approach has emerged: Direct-to-Inject (DTI) buprenorphine. By changing how medication is introduced into the body, DTI offers a safer, more comfortable pathway into recovery without requiring patients to go through days of intense sickness first. This blog breaks down the science behind this modern approach, explains why it beats older induction models, and details exactly how MATClinics is implementing this protocol to help patients reclaim their lives.

What is Direct-to-Inject (DTI) Buprenorphine?

At its core, Direct-to-Inject (DTI) is a medical strategy where a patient transitions onto a long-acting injectable form of buprenorphine (Brixadi© or Sublocade©) without taking any sublingual tablets or films first. Historically, drug safety guidelines required doctors to give patients a small sublingual dose first to make sure they tolerated the medicine. In the fentanyl era, that test dose itself is frequently what triggers the severe sickness patients dread.

DTI flips this approach completely on its head. Instead of an oral film that dumps medicine into the bloodstream all at once, a trained clinician administers a weekly extended-release injection into the subcutaneous fat tissue. The medicine dissolves into the body at a remarkably slow, steady pace, taking a full 24 hours to reach its peak level. Because the medication builds up gradually, it gently takes over the brain’s opioid receptors rather than knocking old drugs off abruptly. This minimizes or completely avoids the shock to the nervous system that causes precipitated withdrawal.

The Balance Analogy: Think of the brain's opioid receptors as a crowded parking lot. Taking an under-the-tongue film is like a fast-moving fleet of tow trucks rushing into the lot all at once, forcefully smashing into existing cars to clear them out. A Direct-to-Inject treatment is like a single slow vehicle circling the lot, gradually taking empty spots as other cars naturally drive away over 24 hours. The lot gets cleared, but without a single collision.

Why DTI is Better Than Standard Induction Options

To understand why Direct-to-Inject is such a massive leap forward, it helps to compare it directly to the older methods clinicians have used to start patients on recovery medications. Medical providers generally have four traditional pathways, each presenting significant drawbacks for someone using fentanyl. 

• Standard (Withdrawal-First) Induction: This requires a patient to stop using all opioids and wait until they are in moderate-to-severe withdrawal before taking their first dose. With fentanyl, patients often have to wait painful hours to reach a safe starting point. Asking someone to endure days of agonizing sickness while trying to start recovery is a massive barrier that frequently leads to treatment failure.
• Microdosing (Very Low-Dose) Protocols: This approach allows patients to keep using full-agonist opioids while taking microscopic, slowly increasing doses of sublingual buprenorphine over several days or weeks. While it minimizes withdrawal, it requires a complex schedule of splitting tiny films, takes an average of 8 days to complete, and means the patient must continue using illegal street drugs to stay stable during the transition.
• Macrodosing (High-Dose) Induction: This relies on giving very large sublingual doses all at once to try and overpower the fentanyl. While successful in some emergency departments, it still requires the patient to wait at least 12 hours in withdrawal before starting, making outpatient use logistically challenging.
• Naloxone-Induced Rapid Transition: This is an aggressive approach where a patient purposefully takes intranasal naloxone (Narcan) to force themselves into a sudden, severe withdrawal crisis, immediately followed by a large sublingual dose. While fast, patients experience approximately 30 to 45 minutes of intense physical distress that does not appeal to everyone.

Direct-to-Inject removes these trade-offs. Because the injection introduces the medicine smoothly over days rather than minutes, patients do not have to put their lives on hold, do not have to split tiny films into fractions, and do not have to purposefully make themselves violently ill to get help.

Initiation Strategies

• Standard Induction: This approach requires a long period of abstinence before treatment can begin. It is moderately complex because withdrawal symptoms must be tracked closely. For many patients, the experience can be highly distressing and difficult to tolerate.
• Microdosing: This approach does not require a wait time, but it often involves continued use of street opioids during the process. It is very complex because it follows a multi-day dosing schedule. While withdrawal symptoms may be lower, the prolonged risk period can be a major concern.
• Macrodosing: This approach typically requires at least 12 hours of withdrawal before treatment begins. It has a medium level of complexity because symptoms must be directly monitored. The patient experience can be unpredictable and is mostly limited to facility-based settings.
• Rapid Narcan Induction: This approach can begin within 2 to 3 hours. It is highly complex because it requires premedication and close symptom tracking. The experience can be highly distressing and difficult to tolerate.
• Direct-to-Inject (DTI): This approach can begin within 0 to 12 hours and may be started while a person is still actively using opioids. It is lower in complexity because treatment is administered through clinic-based injections. For patients, it is often highly tolerable, with mostly mild symptoms.

How MATClinics Does Direct-to-Inject: The Clinical Pathways

At MATClinics, care is never one-size-fits-all. The clinical team looks at each person's unique lifestyle, schedule, and current drug habits to build a customized plan. This is no different for methods of buprenorphine induction. If a patient is identified as a candidate for a DTI induction, they are guided down one of three specific pathways based on a single vital question: How often can you realistically get to our clinic? 

Pathway A: The 3-Day Consecutive Track (Best for Active Users)

This pathway is designed for individuals who are actively using full-agonist opioids like fentanyl or heroin, have little to no baseline withdrawal (a Clinical Opiate Withdrawal Scale, or COWS, score between 0 and 3), and can visit the clinic three days in a row.

• Day 1: The patient receives an initial injection of weekly Brixadi (8mg). They are instructed to continue their normal routine and full-agonist use. A specialized "Comfort Bundle" of non-opioid medications is prescribed to treat any baseline symptoms.
• Day 2: At least 24 hours later, the patient returns for a weekly Brixadi (16mg) injection. This step safely steps up the buprenorphine shield in their system.
• Day 3: The transition is finalized with a long-term monthly injection (either Brixadi 128mg or Sublocade 300mg) to provide a steady, month-long protective layer against cravings and overdoses.

Pathway B: The 2-Day Consecutive Track (Best for Early Withdrawal)

If a patient has already stopped using opioids for at least 6 to 12 hours and is beginning to feel early signs of natural withdrawal (a COWS score of 4 or higher), they qualify for the faster 2-day track.

• Day 1: Because the patient's receptors are already starting to clear out naturally, the clinician can skip the lowest dose and immediately give a weekly Brixadi (16mg) injection alongside the comfort medication bundle.
• Day 2: Exactly 24 hours later, the patient returns to receive their full monthly maintenance injection (Brixadi 128mg or Sublocade 300mg). This completes the induction in just 48 hours.

Pathway C: The Weekly Visit Track (Best for High Logistical Barriers)

MATClinics recognizes that structural challenges like housing instability, work schedules, or lack of transportation make it impossible for some patients to visit a clinic multiple days in a row. For these individuals, the protocol offers a high-dose single-visit track:

• Day 1 (Initial Loading): The patient receives a full, therapeutic "macrodose" injection immediately on their very first visit (either weekly Brixadi 32mg or a monthly Sublocade 300mg injection) to quickly build a protective layer. They are sent home with a robust support plan and the Comfort Bundle.
• Week 2 (Day 8 Follow-Up): The patient returns one week later to evaluate their symptoms and smoothly transition directly onto a standard monthly injection schedule.

What is the "Comfort Bundle"? Supporting Patients Through the Transition

Even though Direct-to-Inject is vastly more comfortable than older methods, transitioning your body off of street drugs still takes effort. To make sure no patient has to suffer through breakthrough symptoms, MATClinics provides every DTI patient with a standardized Comfort Adjunct Bundle order set on Day 1. This toolkit treats specific physical symptoms using safe, non-addictive medications. Patients inducting onto buprenorphine through other methods are prescribed similar comfort medications as well. 

• Clonidine (0.2mg): Taken as needed to calm down restlessness, rapid heartbeats, sweating, and hot flashes.
• Ondansetron ODT (4mg): A fast-acting, dissolving under-the-tongue tablet used to completely halt nausea or vomiting.
• Hydroxyzine (50mg): Used to treat acute anxiety, muscle tension, and nervousness.
• Methocarbamol (500mg) & Ibuprofen (600mg): Used in combination to stop deep muscle spasms, joint pain , and body aches.
• Dicyclomine (20mg) & Loperamide (2mg): Specifically targeted medications to eliminate abdominal cramps and loose stools.
• Trazodone (50mg): Taken at bedtime to assist with insomnia and help the brain get restful sleep.
• Naloxone (Narcan) Nasal Spray: A lifesaving rescue pack distributed to every patient for safety.

The Benefits and Risks of Direct-to-Inject

Like any medical treatment, it is important to weigh the advantages against the potential side effects so you can make an informed choice alongside your doctor.

The Clear Benefits

• High Success and Retention Rates: Major clinical data tracking outpatient DTI protocols showed that between 68% and 73% of patients successfully stayed on their medication at the 30-day mark. For comparison, traditional outpatient microdosing methods in similar populations often see retention rates drop significantly lower because the multi-day hurdle is simply too complex to manage.
• Freedom from Daily Medication: Once a patient receives the monthly injection, they no longer have to remember to take a sublingual film or tablet every single day, eliminating the risk of losing their medication.
• Immediate Safety Net: The long-acting injection creates a steady baseline level of medication in the blood that lasts for weeks. If a patient experiences a momentary lapse and uses a street drug, the injection acts as a protective shield, drastically reducing the risk of a fatal overdose.

The Potential Risks & What to Expect

• Mild to Moderate Transitional Discomfort: Data shows that while many patients feel absolutely no withdrawal symptoms during a DTI transition, a portion will feel mild-to-moderate symptoms (like feeling hot, sluggish, or "under the weather") during the first 24 hours. These symptoms are expected and highly manageable using the Comfort Bundle and “use” of their own supply of full opioid agonists.
• Severe Breakthrough Symptoms (Rare): Across extensive outpatient research, around 11% of individuals experienced a rougher transition with severe physical symptoms. However, the studies noted a vital piece of good news: 80% of the patients who had a rough first day still chose to come back for their next injection because they knew they were turning a corner.
• Dose Stacking Considerations: Because long-acting injections stay in the fat tissue for an extended period, doctors must carefully space injections out (typically waiting at least 24 to 48 hours between doses) to avoid "stacking" too much medicine in the body at once.

Conclusion: Taking the First Step without Fear

The transition into recovery should be a moment of hope, not a period of dread. The emergence of Direct-to-Inject buprenorphine represents one of the most compassionate and scientifically sound advancements in modern addiction medicine. By erasing the requirement of long, agonizing withdrawal periods, it meets patients exactly where they are—even if they used fentanyl just a few hours before walking into a clinic.

Through flexible clinical pathways, a comprehensive tracking system, and dedicated symptom-management bundles, MATClinics is proving that the barriers of the past do not have to dictate your future. If you are ready to explore an easier, safer path to long-term freedom from opioids, reach out to MATClinics today to find out if the Direct-to-Inject track is right for you.